Abstract:To reveal the clinical significance of the expressions of receptor of advanced glycation end product (RAGE) and soluble RAGE (sRAGE) in gastric cancer and their correlations with tumor differentiation. Methods To study the expression of RAGE in gastric carcinoma tissues, the paraffin-embedded cancerous tissues of 38 patients with stageⅠ-Ⅲgastric cancer without diabetes mellitus were enrolled in this study and 10 samples of adjacent tissues (distance from the edge of the cancer tissues ≥5 cm) as control group. RAGE was analyzed by immunohistochemical staining. To detect the concentration of serum sRAGE, peripheral blood of the 38 gastric cancer patients was collected about 24 hours before operation and on the 7th day after surgery, and the peripheral blood of 30 healthy donors was collected as control group. The concentration of serum sRAGE was analyzed by enzyme-linked immunosorbent assay. Results RAGE was expressed in the adjacent tissues and the gastric tumor tissues, but higher in the gastric tumor tissues (p <0.05). RAGE was not correlated with TNM stage or pathological type of the cancer (p > 0.05). The expression levels of preoperative and postoperative serum sRAGE from the 38 patients with gastric cancer were higher than that from the healthy donors (p < 0.05). The sRAGE expression level decreased after radical gastrectomy (p < 0.05). After the surgery, compared with the patients with stage Ⅱor Ⅲgastric cancer, the patients with stage Ⅰgastric cancer had a lower expression level of serum sRAGE (p < 0.05). Conclusions RAGE expression is up-regulated in gastric tumor tissues, and is helpful to histopathological diagnosis. Serum sRAGE concentration increases in the patients with stage I-Ⅲgastric cancer, which expresses a certain clinical significance in preoperative tumor screening.